Article

Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3

2020-06-03

Abstract excerpt

Histone deacetylases (HDACs) remove acetyl groups from histone proteins and are implicated in gene regulation. They have been recognized as drug targets for treatment of cancer and other human diseases and several inhibitors are already clinically used. Here, we report the design, synthesis, and cellular characterization of a proteolysis-targeting chimera (PROTAC) capable of selectively degrading class I HDACs 1–3...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c9a7938-630b-5240-aaf1-c9a76dba15d6
DOI: 10.26434/chemrxiv.12416303.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3DOI 10.26434/chemrxiv.12416303.v1Read

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective InhibitorsSemantic proximity Read

Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor DegradersSemantic proximity Read

Developing potent PROTACs tools for selective degradation of HDAC6 proteinSemantic proximity Read

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug ResistanceSemantic proximity Read

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read

Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo TractabilitySemantic proximity Read

Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitorSemantic proximity Read

DCAF16-Based Covalent Degradative Handles for the Modular Design of DegradersSemantic proximity Read

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read

Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53.Semantic proximity Read

Medicinal chemistry advances in targeting class I histone deacetylasesSemantic proximity Read

PROTACs: great opportunities for academia and industrySemantic proximity Read